Lantheus to Present at Upcoming Investor Conferences
February 21, 2025 08:30 ET | Source: Lantheus Holdings, Inc. BEDFORD, Mass.,…
Teva and Sanofi Present New Positive Phase 2b Study Results at ECCO 2025 ReinforcingBest-in-Class Potential of Duvakitug (Anti-TL1A) in Ulcerative Colitis and Crohns Disease
Teva hosting investor call Monday, February 24 at 8:00 a.m. U.S. ET…
Visit Dubai Partners with Indian Couturier Gaurav Gupta to Present Dubai-Inspired Capsule Collection
As a leading couturier known for merging indigenous Indian designs and embellishing techniques…
Arcutis to Present at the TD Cowen 45th Annual Health Care Conference
WESTLAKE VILLAGE, Calif., Feb. 18, 2025 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq:…
Longeveron to Present at the Emerging Growth Virtual Conference on February 19, 2025
MIAMI, Feb. 14, 2025 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a…
ICU Medical to Present at the Raymond James 46th Annual Institutional Investors Conference
February 13, 2025 16:05 ET | Source: ICU Medical, Inc. SAN CLEMENTE,…
Kia to Present Global EV Leadership Strategy and Key Models at 2025 Kia EV Day
Kia to announce expanded global EV leadership strategy at 2025 Kia EV…
CRISPR Therapeutics to Present at the Guggenheim SMID Cap Biotech Conference
January 29, 2025 08:00 ET | Source: CRISPR Therapeutics AG ZUG, Switzerland…
Akero Therapeutics to Present Preliminary Topline Week 96 Results from Phase 2b SYMMETRY Study Investigating Efruxifermin in Patients with Compensated Cirrhosis (F4) Due to MASH
January 24, 2025 16:05 ET | Source: Akero Therapeutics Inc. Investor webcast…
Akero Therapeutics to Present Preliminary Topline Week 96 Results from Phase 2b SYMMETRY Study Investigating Efruxifermin in Patients with Compensated Cirrhosis (F4) Due to MASH
January 24, 2025 16:05 ET | Source: Akero Therapeutics Inc. Investor webcast…